Literature DB >> 11371962

Angiogenesis and angiogenic growth factors in Wilms tumor.

E G Sköldenberg1, J Christiansson, B Sandstedt, A Larsson, G Läckgren, R Christofferson.   

Abstract

PURPOSE: Angiogenesis, that is new blood vessel formation, is a prerequisite for growth and metastasis of solid tumors. This study was undertaken to quantify tumor capillaries, investigate immunohistochemical expression and measure serum concentrations of angiogenic growth factors in patients with Wilms tumor.
MATERIALS AND METHODS: The hospital records of 33 patients were reviewed and new slides were stained for the endothelial cell marker CD31. Capillaries were quantified in the most vascularized part of the tumor (hot spot) and in the whole slide. New slides were stained immunohistochemically for the angiogenic growth factors angiogenin, basic fibroblast growth factor (bFGF), transforming growth factor alpha, transforming growth factor beta1-3, tumor necrosis factor alpha and vascular endothelial growth factor (VEGF), and their immunoreactivity was quantified. Pretreatment serum samples from 14 patients and 56 healthy control children were analyzed using enzyme-linked immunosorbent assay kits for angiogenin, basic fibroblast growth factor, epidermal growth factor, hepatocyte growth factor, tumor necrosis factor alpha and VEGF.
RESULTS: Logistic regression analysis and Kaplan-Meier estimates showed that quantifications based on the tumor hot spot had a significant impact on survival probability (p <0.05). The tumor hot spot counts were highest in the blastemal compartment. Levels of hepatocyte growth factor and VEGF in serum were 3 times higher than those in controls (p <0.01).
CONCLUSIONS: Although the sample size is small in this study, the results imply that angiogenesis in Wilms tumor is driven by angiogenic growth factors, and that intratumoral capillary quantification and determinations of serum levels of angiogenic growth factors may be of clinical value.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11371962     DOI: 10.1097/00005392-200106001-00015

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  12 in total

1.  A therapeutic target for prostate cancer based on angiogenin-stimulated angiogenesis and cancer cell proliferation.

Authors:  Norie Yoshioka; Li Wang; Koji Kishimoto; Takanori Tsuji; Guo-fu Hu
Journal:  Proc Natl Acad Sci U S A       Date:  2006-09-13       Impact factor: 11.205

2.  A phase 1 study of the c-Met inhibitor, tivantinib (ARQ197) in children with relapsed or refractory solid tumors: A Children's Oncology Group study phase 1 and pilot consortium trial (ADVL1111).

Authors:  James I Geller; John P Perentesis; Xiaowei Liu; Charles G Minard; Rachel A Kudgus; Joel M Reid; Elizabeth Fox; Susan M Blaney; Brenda J Weigel
Journal:  Pediatr Blood Cancer       Date:  2017-04-27       Impact factor: 3.167

Review 3.  tRNA fragmentation and protein translation dynamics in the course of kidney injury.

Authors:  Iadh Mami; Nicolas Pallet
Journal:  RNA Biol       Date:  2018-02-12       Impact factor: 4.652

Review 4.  Scatter factor/hepatocyte growth factor in brain tumor growth and angiogenesis.

Authors:  Roger Abounader; John Laterra
Journal:  Neuro Oncol       Date:  2005-10       Impact factor: 12.300

5.  Angiogenin expression in human kidneys and Wilms' tumours: relationship with hypoxia and angiogenic factors.

Authors:  Pramila Ramani; Alison Headford; Emile Sowa-Avugrah; Linda P Hunt
Journal:  Int J Exp Pathol       Date:  2013-02-19       Impact factor: 1.925

Review 6.  Angiogenin-mediated ribosomal RNA transcription as a molecular target for treatment of head and neck squamous cell carcinoma.

Authors:  Lili Chen; Guo-fu Hu
Journal:  Oral Oncol       Date:  2010-07-24       Impact factor: 5.337

7.  Microarray analysis of somatostatin receptor 5-regulated gene expression profiles in murine pancreas.

Authors:  Sanjeet G Patel; Guisheng Zhou; Shi-He Liu; Min Li; Jae-Wook Jeong; Francesco J DeMayo; Marie-Claude Gingras; Richard A Gibbs; William E Fisher; F Charles Brunicardi
Journal:  World J Surg       Date:  2009-04       Impact factor: 3.352

8.  Expression and prognostic relevance of vascular endothelial growth factor (VEGF) and its receptor (FLT-1) in nephroblastoma.

Authors:  M A Ghanem; G J van Steenbrugge; M K Sudaryo; R B Mathoera; J M Nijman; Th H van der Kwast
Journal:  J Clin Pathol       Date:  2003-02       Impact factor: 3.411

9.  A Novel Extrinsic Pathway for the Unfolded Protein Response in the Kidney.

Authors:  Iadh Mami; Quentin Tavernier; Nicolas Bouvier; Rim Aboukamis; Geoffroy Desbuissons; Marion Rabant; Virginie Poindessous; Pierre Laurent-Puig; Philippe Beaune; Pierre-Louis Tharaux; Eric Thervet; Eric Chevet; Dany Anglicheau; Nicolas Pallet
Journal:  J Am Soc Nephrol       Date:  2016-01-28       Impact factor: 10.121

10.  WT1 mutants reveal SRPK1 to be a downstream angiogenesis target by altering VEGF splicing.

Authors:  Elianna M Amin; Sebastian Oltean; Jing Hua; Melissa V R Gammons; Maryam Hamdollah-Zadeh; Gavin I Welsh; Man-Kim Cheung; Lan Ni; Satoru Kase; Emma S Rennel; Kirsty E Symonds; Dawid G Nowak; Brigitte Royer-Pokora; Moin A Saleem; Masatoshi Hagiwara; Valérie A Schumacher; Steven J Harper; David R Hinton; David O Bates; Michael R Ladomery
Journal:  Cancer Cell       Date:  2011-12-13       Impact factor: 31.743

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.